BACKGROUND: This study explored phosphodiesterase type 5 (PDE5) inhibition as a strategy for treating high altitude pulmonary arterial hypertension (HAPH). METHODS:689 subjects (313 men) of mean (SD) age 44 (0.6) years living above 2500 m were screened for HAPH by medical examination and electrocardiography, and 188 (27%) met the criteria for right ventricular hypertrophy. 44 underwent cardiac catheterisation and 29 (66%) had a resting mean pulmonary artery pressure (PAP) above 25 mmHg. 22 patients with araised mean PAP were randomised to receive sildenafil (25 or 100 mg) or matching placebo taken 8 hourly for 12 weeks. RESULTS: At 3 months, patients on sildenafil 25 mg 8 hourly (n = 9) had a significantly (p = 0.018) lower mean PAP (-6.9 mmHg) at the end of the dosing interval than those on placebo (n = 8) (95% CI -12.4 to -1.3). The treatment effect for sildenafil 100 mg 8 hourly (n = 5) compared with placebo was -6.4 mm Hg (95% CI -12.9 to 0.1). Both doses improved 6 minute walk distance, the lower dose by 45.4 m (95% CI 11.5 to 79.4; p = 0.011) and the higher dose by 40.0 m (95% CI 0.2 to 79.8; p = 0.049). Sildenafil was well tolerated. Necroscopic lung specimens from three subjects withHAPH showed abundant PDE5 in the muscular coat of remodelled pulmonary arterioles. CONCLUSIONS:PDE5 is an attractive drug target for the treatment of HAPH and a larger study of the long term effects of PDE5 inhibition in HAPH is warranted.
RCT Entities:
BACKGROUND: This study explored phosphodiesterase type 5 (PDE5) inhibition as a strategy for treating high altitude pulmonary arterial hypertension (HAPH). METHODS: 689 subjects (313 men) of mean (SD) age 44 (0.6) years living above 2500 m were screened for HAPH by medical examination and electrocardiography, and 188 (27%) met the criteria for right ventricular hypertrophy. 44 underwent cardiac catheterisation and 29 (66%) had a resting mean pulmonary artery pressure (PAP) above 25 mmHg. 22 patients with a raised mean PAP were randomised to receive sildenafil (25 or 100 mg) or matching placebo taken 8 hourly for 12 weeks. RESULTS: At 3 months, patients on sildenafil 25 mg 8 hourly (n = 9) had a significantly (p = 0.018) lower mean PAP (-6.9 mmHg) at the end of the dosing interval than those on placebo (n = 8) (95% CI -12.4 to -1.3). The treatment effect for sildenafil 100 mg 8 hourly (n = 5) compared with placebo was -6.4 mm Hg (95% CI -12.9 to 0.1). Both doses improved 6 minute walk distance, the lower dose by 45.4 m (95% CI 11.5 to 79.4; p = 0.011) and the higher dose by 40.0 m (95% CI 0.2 to 79.8; p = 0.049). Sildenafil was well tolerated. Necroscopic lung specimens from three subjects with HAPH showed abundant PDE5 in the muscular coat of remodelled pulmonary arterioles. CONCLUSIONS:PDE5 is an attractive drug target for the treatment of HAPH and a larger study of the long term effects of PDE5 inhibition in HAPH is warranted.
Authors: G Cattoretti; S Pileri; C Parravicini; M H Becker; S Poggi; C Bifulco; G Key; L D'Amato; E Sabattini; E Feudale Journal: J Pathol Date: 1993-10 Impact factor: 7.996
Authors: Evangelos D Michelakis; Wayne Tymchak; Michelle Noga; Linda Webster; Xi-Chen Wu; Dale Lien; Shao-Hua Wang; Dennis Modry; Stephen L Archer Journal: Circulation Date: 2003-10-20 Impact factor: 29.690
Authors: Hossein A Ghofrani; Frank Reichenberger; Markus G Kohstall; Eike H Mrosek; Timon Seeger; Horst Olschewski; Werner Seeger; Friedrich Grimminger Journal: Ann Intern Med Date: 2004-08-03 Impact factor: 25.391
Authors: Ralph T Schermuly; Klaus P Kreisselmeier; Hossein A Ghofrani; Hüseyin Yilmaz; Ghazwan Butrous; Leander Ermert; Monika Ermert; Norbert Weissmann; Frank Rose; Andreas Guenther; Dieter Walmrath; Werner Seeger; Friedrich Grimminger Journal: Am J Respir Crit Care Med Date: 2003-09-04 Impact factor: 21.405
Authors: Ghada W Mikhail; Sanjay K Prasad; Wei Li; Paula Rogers; Adrian H Chester; Stephanie Bayne; David Stephens; Mohammed Khan; J S R Gibbs; Timothy W Evans; Andrew Mitchell; Magdi H Yacoub; Michael A Gatzoulis Journal: Eur Heart J Date: 2004-03 Impact factor: 29.983
Authors: Robert W Gotshall; Karyn L Hamilton; Benjamin Foreman; Martha C Tissot van Patot; David C Irwin Journal: Crit Care Med Date: 2009-06 Impact factor: 7.598
Authors: Giuseppina Milano; Paola Bianciardi; Viviane Rochemont; Giuseppe Vassalli; Ludwig K von Segesser; Antonio F Corno; Marco Guazzi; Michele Samaja Journal: PLoS One Date: 2011-11-28 Impact factor: 3.240